SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms
Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
This study aims to investigate whether substitution of Efavirenz (EFV) as the
Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) fixed-dose combination (FDC) Atripla, with
Rilpivirine as the tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV) fixed-dose combination
(FDC) Eviplera, leads to resolution of covert Central Nervous System (CNS) toxicity
associated with EFV, continued virological suppression and immunological reconstitution and
whether this is associated with an improvement in quality of life, sleep, anxiety/depression
and neurocognitive function; the impact of switch on adherence will also be investigated.
Phase:
Phase 4
Details
Lead Sponsor:
St Stephens Aids Trust
Collaborator:
Gilead Sciences
Treatments:
Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Emtricitabine Rilpivirine Tenofovir